Lycia Therapeutics
PrivateLast Round
Series D
Jun 25, 2026
Total Funding Raised
$301.6M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Lycia Therapeutics is a biotechnology company that discovers and develops first-in-class therapeutics using a lysosomal targeting chimeras platform to degrade extracellular and membrane-bound proteins associated with challenging diseases like cancers and autoimmune conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Lycia Therapeutics Comparables
Compare Lycia Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Plexium | 87% | |
| Avilar Therapeutics | 85% | |
| Amphista Therapeutics | 82% |
Lycia Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Jun 25, 2026 | ||||
| Series C | May 13, 2024 | ||||
| Series B | Sep 9, 2021 | ||||
| Series A | Jun 9, 2020 |
Lycia Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series C, Series B |
| Owl Rock Capital Group | Series C |
| Janus Henderson Group | Series C, Series D |
| Balyasny Asset Management L.P. | Series D |
| Franklin Advisers | Series C |
| Franklin Templeton | Series D, Series C |
| TD Securities | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 25, 2026
$75M round led by Balyasny Asset Management and Janus Henderson.
- Feb 7, 2025
Chin Lee, M.D., M.P.H. appointed as new chief medical officer.
Recent news
Latest coverage and updates
- goes_publicOct 6, 2026
Lycia Therapeutics, Inc. files for an initial public offering
Lycia Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Lycia Therapeutics's valuation, stock price, and market status.
Is Lycia Therapeutics a public or private company?
Lycia Therapeutics is a private company.
What is the current stock price of Lycia Therapeutics?
Lycia Therapeutics is a private company, so its shares have no public market price. Caplight tracks Lycia Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Lycia Therapeutics worth (valuation)?
Valuation information for Lycia Therapeutics is not publicly available.
Can I buy Lycia Therapeutics stock?
Lycia Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Lycia Therapeutics's last funding round?
Lycia Therapeutics's most recent funding round was Series D on June 25, 2026.
Who are the main investors in Lycia Therapeutics?
Key investors in Lycia Therapeutics include Redmile Group, Janus Henderson Group, Balyasny Asset Management L.P., Versant Ventures, Venrock.
Will Lycia Therapeutics IPO soon?
No public IPO plans have been announced for Lycia Therapeutics.
How can I track Lycia Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Lycia Therapeutics's shares on secondary markets.